NCT04129099 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

June 30, 2022

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

GC022F

GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.

Trial Locations (1)

065200

RECRUITING

Hebei Yanda Ludaopei Hospital, Sanhe